Telomir Pharmaceuticals Secures FDA IND Clearance for Telomir-Zn in Breast Cancer
TELO sits 42% above its 52-week low of $1.05 on elevated volume (1.9× avg).
Summary
Telomir Pharmaceuticals announced FDA clearance of its Investigational New Drug (IND) application for Telomir-Zn, enabling the initiation of a Phase 1/2 clinical trial for triple-negative breast cancer.
Key Events · Product Development and Regulatory · TELO
-
FDA IND Clearance
The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for Telomir-Zn.
-
Target Indication
Telomir-Zn is being developed for the treatment of patients with advanced or metastatic triple-negative breast cancer.
-
Clinical Trial Initiation
The company plans to initiate a First-in-Human Phase 1/2 clinical trial in the first half of 2026.
-
Trial Design
The planned study will include a dose-escalation Phase 1 for safety and preliminary activity, followed by a Phase 2 portion evaluating objective response rate (ORR) as the primary endpoint.
Analysis · TELO · Life Sciences
This FDA clearance is a critical milestone for Telomir Pharmaceuticals, allowing them to advance their lead product candidate, Telomir-Zn, into human clinical trials. For a company previously noted with a going concern warning, this progress in their drug development pipeline provides a significant positive signal, demonstrating tangible advancement towards potential future commercialization. The planned Phase 1/2 trial will assess safety, tolerability, and preliminary efficacy, with results being crucial for the company's long-term viability and investor confidence.
At the time of this filing, TELO was trading at $1.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.9M. The 52-week trading range was $1.05 to $3.10. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.